Format
Sort by

Send to

Choose Destination

Search results

Items: 20

1.

Prediction of the flooding of a mining reservoir in NW Spain.

Álvarez R, Ordóñez A, De Miguel E, Loredo C.

J Environ Manage. 2016 Dec 15;184(Pt 2):219-228. doi: 10.1016/j.jenvman.2016.09.072.

PMID:
27720329
2.

Hydrochemical characterization of a mine water geothermal energy resource in NW Spain.

Loredo C, Ordóñez A, Garcia-Ordiales E, Álvarez R, Roqueñi N, Cienfuegos P, Peña A, Burnside NM.

Sci Total Environ. 2016 Oct 22;576:59-69. doi: 10.1016/j.scitotenv.2016.10.084. [Epub ahead of print]

PMID:
27780100
3.

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.

Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE.

PLoS One. 2016 May 9;11(5):e0154778. doi: 10.1371/journal.pone.0154778.

4.

Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.

Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium..

Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v. doi: 10.5588/ijtld.14.0829.

5.

Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.

Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group.; Tuberculosis Trials Consortium..

JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. Erratum in: JAMA Pediatr. 2015 Sep;169(9):878.

PMID:
25580725
6.

Yield of close contact tracing using two different programmatic approaches from tuberculosis index cases: a retrospective quasi-experimental study.

Loredo C, Cailleaux-Cezar M, Efron A, de Mello FC, Conde MB.

BMC Pulm Med. 2014 Aug 7;14:133. doi: 10.1186/1471-2466-14-133.

7.

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium..

J Infect Dis. 2012 Oct 1;206(7):1030-40.

8.

Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment.

Bliven-Sizemore EE, Johnson JL, Goldberg S, Burman WJ, Villarino ME, Chaisson RE; Tuberculosis Clinical Trials Consortium..

Int J Tuberc Lung Dis. 2012 Apr;16(4):473-9. doi: 10.5588/ijtld.11.0548.

PMID:
22325844
9.

Three months of rifapentine and isoniazid for latent tuberculosis infection.

Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team..

N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875.

10.

Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis.

Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M; Tuberculosis Trials Consortium..

PLoS One. 2010 May 20;5(5):e10753. doi: 10.1371/journal.pone.0010753.

11.

Point-of-care Arkansas method for measuring adherence to treatment with isoniazid.

Guerra RL, Conde MB, Efron A, Loredo C, Bastos G, Chaisson RE, Golub JE.

Respir Med. 2010 May;104(5):754-7. doi: 10.1016/j.rmed.2010.02.001.

12.

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium..

Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC.

PMID:
19406981
13.

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.

Conde MB, Efron A, Loredo C, De Souza GR, Graça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE.

Lancet. 2009 Apr 4;373(9670):1183-9. doi: 10.1016/S0140-6736(09)60333-0.

14.

T-SPOT.TB responses during treatment of pulmonary tuberculosis.

Ribeiro S, Dooley K, Hackman J, Loredo C, Efron A, Chaisson RE, Conde MB, Boechat N, Dorman SE.

BMC Infect Dis. 2009 Feb 28;9:23. doi: 10.1186/1471-2334-9-23.

15.

Role of IFN-gamma +874 T/A single nucleotide polymorphism in the tuberculosis outcome among Brazilians subjects.

Amim LH, Pacheco AG, Fonseca-Costa J, Loredo CS, Rabahi MF, Melo MH, Ribeiro FC, Mello FC, Oliveira MM, Lapa e Silva JR, Ottenhoff TH, Kritski AL, Santos AR.

Mol Biol Rep. 2008 Dec;35(4):563-6.

PMID:
17682837
16.

Fetal intermediate rhabdomyoma of the lip: case report.

Fernández JM, Medlich MA, López LH, Loredo CF, Luque LC.

J Clin Pediatr Dent. 2005 Winter;29(2):179-80.

PMID:
15719926
17.

Thalidomide--effect on T cell subsets as a possible mechanism of action.

Moncada B, Baranda ML, González-Amaro R, Urbina R, Loredo CE.

Int J Lepr Other Mycobact Dis. 1985 Jun;53(2):201-5.

PMID:
3874920
18.

Immunopathology of polymorphous light eruption. T lymphocytes in blood and skin.

Moncada B, González-Amaro R, Baranda ML, Loredo C, Urbina R.

J Am Acad Dermatol. 1984 Jun;10(6):970-3.

PMID:
6234329
19.

Treatment of onychomycosis with ketoconazole and nonsurgical avulsion of the affected nail.

Moncada B, Loredo CE, Isordia E.

Cutis. 1983 Apr;31(4):438-40.

PMID:
6303711
20.

[Langerhans cells in leprosy].

Moncada B, González-Amaro R, Loredo CE, Baranda ML.

Gac Med Mex. 1982 Dec;118(12):497-504. Spanish. No abstract available.

PMID:
6764439
Items per page

Supplemental Content

Loading ...
Support Center